Drugmaker Novo Nordisk expects Wegovy weight-loss drug sales in the United States to start to recover once a ban on compound copycats is enforced this month, its CEO said on Wednesday after the company cut its 2025 forecasts.

The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the rival medicines.

Novo Nordisk is hedging and building its way around a global tariff war that may threaten the Wegovy maker’s plans to expand in the U.S. Karsten Munk Knudsen, Novo Nordisk’s chief financial officer, told Fortune the company is well-placed to handle the geopolitical upheaval that rocked global business in March and April.

Pedersen and Maggie Fick COPENHAGEN/LONDON (Reuters) -Obesity drugmaker Novo Nordisk cut its sales forecasts on Wednesday for the first time since the launch of its Wegovy weight-loss drug four years ago,

Novo Nordisk A/S said it would sell its popular weight-loss drug Wegovy for a steeply reduced price on several telehealth platforms. The strategy comes as rival Eli Lilly & Co. is working with telehealth firms to distribute lower-cost vials of its own obesity medication,

We came across a bullish thesis on Novo Nordisk A/S (NVO) on Substack by Kontra Investments. In this article, we will summarize the bulls’ thesis on NVO.

Aetna is once again retreating from the Affordable Care Act market, while its parent company notched a deal with Danish drugmaker Novo Nordisk that should expand access to its in-demand GLP-1 at the expense of Eli Lilly’s.

Within six months, the drug reduced the risk of cardiovascular death by 50 and cut the risk of needing urgent treatment due to heart failure.